Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data
Similarity Data To Be Presented At 2021 ARVO Meeting
Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.
